AIDS Res Hum Retroviruses. 2016 Feb;32(2):109-19. doi: 10.1089/AID.2015.0258.
Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID “Meet the Experts” 2015 Workshop Summary.
Akkina R1, Allam A2,3, Balazs AB4, Blankson JN5, Burnett JC6, Casares S7, Garcia JV8, Hasenkrug KJ9, Kashanchi F10, Kitchen SG11, Klein F12,13, Kumar P14, Luster AD15, Poluektova LY16, Rao M3, Sanders-Beer BE17, Shultz LD18, Zack JA11
The number of humanized mouse models for the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and other infectious diseases has expanded rapidly over the past 8 years. Highly immunodeficient mouse strains, such as NOD/SCID/gamma chain(null) (NSG, NOG), support better human hematopoietic cell engraftment. Another improvement is the derivation of highly immunodeficient mice, transgenic with human leukocyte antigens (HLAs) and cytokines that supported development of HLA-restricted human T cells and heightened human myeloid cell engraftment. Humanized mice are also used to study the HIV reservoir using new imaging techniques. Despite these advances, there are still limitations in HIV immune responses and deficits in lymphoid structures in these models in addition to xenogeneic graft-versus-host responses. To understand and disseminate the improvements and limitations of humanized mouse models to the scientific community, the NIH sponsored and convened a meeting on April 15, 2015 to discuss the state of knowledge concerning these questions and best practices for selecting a humanized mouse model for a particular scientific investigation. This report summarizes the findings of the NIH meeting.